Press-release for stocks related to pharm-country

Prices are updated after-hours

tags : Pharm-country crawled time : 12:30

save search

Amneal to Report Third Quarter 2023 Results on November 7, 2023
Published: 2023-10-05 (Crawled : 12:30) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M

Health Technology

| 28.57% | O: 0.71% H: 0.95% C: -7.8%
report results

Quantum-Si to Present at The Festival of Genomics & Biodata 2023 in Boston, Massachusetts
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
QSI | $1.7 4.94% 4.71% 630K

Professional, Scientific, and T...

| 8.28% | O: -1.27% H: 1.94% C: -1.94%
genomics

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
ROIV | $10.935 3.16% 3.06% 5M

Manufacturing

| 4.04% | O: -1.0% H: 1.15% C: 0.1%
trial

Henry Schein to Present at Goldman Sachs Global Sustainability Forum
Published: 2023-09-14 (Crawled : 12:30) - biospace.com/
HSIC | $72.79 1.04% 1.03% 630K

Distribution Services

| -0.61% | O: 0.67% H: 1.41% C: 1.02%
global

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection
Published: 2023-09-14 (Crawled : 12:30) - biospace.com/
COEP | $0.355 2.65% 51K

| -65.31% | O: 10.2% H: 0.0% C: -5.56%
dvx201 covid-19 update infection risk trials aml therapeutics

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology
Published: 2023-09-14 (Crawled : 12:30) - biospace.com/
AVXL | $3.68 0.0% 1.4M

Health Technology

| -51.57% | O: 4.18% H: 5.14% C: -0.38%
anavex disease blarcamesine alzheimer’s trial biomarkers anavex®2-73

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment
Published: 2023-09-11 (Crawled : 12:30) - biospace.com/
COEP | $0.355 2.65% 51K

| -67.31% | O: -2.88% H: 4.95% C: -2.48%
life cancer awards research grant therapeutics

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Published: 2023-09-11 (Crawled : 12:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M

Health Technology

| 16.35% | O: 0.25% H: 0.11% C: -0.66%
merck hypertension potential

Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-09-11 (Crawled : 12:30) - biospace.com/
NTRB | $3.255 -8.05% -8.76% 26K

Manufacturing

| 35.88% | O: 5.34% H: 6.81% C: 3.26%
business update financial results

Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022
Published: 2022-03-11 (Crawled : 12:30) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology

| -27.64% | O: 0.58% H: 0.0% C: 0.0%
report results

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple SclerosisMonday, March 14th @ 11 am ET, registration details below
Published: 2022-03-11 (Crawled : 12:30) - biospace.com/
TLSA | News | $0.7501 -0.46% -0.47% 2.5M

Health Technology

| -24.27% | O: -10.58% H: 0.0% C: 0.0%
multiple sclerosis day liver foralumab life science sclerosis ism

Merck Shares Environmental, Social & Governance Priorities and Strategy
Published: 2022-02-23 (Crawled : 12:30) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M

Health Technology

| 67.06% | O: 0.32% H: 0.33% C: -0.46%

Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
MRNS | $1.455 -1.36% -1.37% 2.9M

Health Technology

| -88.0% | O: 0.25% H: 0.83% C: -0.75%
als financial results results

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-16 (Crawled : 12:30) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M

Health Technology

| -27.71% | O: 0.0% H: 0.91% C: -0.25%
cardio trial mavacamten topline results positive topline phase 3

NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021
Published: 2022-02-15 (Crawled : 12:30) - biospace.com/
NNVC | $1.14 1.79% 0.0% 12K

Health Technology

| -48.18% | O: 0.0% H: 8.18% C: 4.09%
report

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
Published: 2022-02-08 (Crawled : 12:30) - biospace.com/
SONN | $1.8 6.19% 5.83% 18K

Health Technology

| 465.08% | O: 1.9% H: 0.0% C: -5.76%
therapeutics iot

AmerisourceBergen Reports Fiscal 2022 First Quarter Results
Published: 2022-02-02 (Crawled : 12:30) - biospace.com/
WBA 4 | $18.05 -0.93% -0.94% 7.3M

Retail Trade

| -63.44% | O: 0.91% H: 0.0% C: 0.0%
report results

Quest Diagnostics Launches COVID-19 Rapid Antigen Test with Observed Collection for Consumers Through QuestDirect™
Published: 2022-01-26 (Crawled : 12:30) - biospace.com/
DGX | News | $136.7 5.08% 0.0% 2.1M

Health Services

| -0.35% | O: -0.58% H: 1.43% C: -0.72%
covid-19 diagnostic diagnostics covid test

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
Published: 2022-01-03 (Crawled : 12:30) - biospace.com/
OVID | $3.19 1.27% 1.25% 110K

Health Technology

| -0.31% | O: 0.0% H: 5.3% C: 4.67%
therapeutics